> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China's revised BE filing rules put study design and trial history in focus
- URL: https://chinapharmadesk.com/china-cde-be-filing-rules/
- Published: 2026-11-13T05:08:58.000Z
- Updated: 2026-11-15T02:54:22.000Z
- Description: CDE Notice No. 51 of 2026 revises China's bioequivalence (BE) filing procedure effective Feb 1, 2027, reshaping CRO study routing, batch traceability and CTD 2.7.1 trial-history duties.
- Author: Lin Yi
- Tags: Desk analysis, Regulation, CRO & Bioequivalence

China's revised bioequivalence filing procedure, due to take effect on February 1, 2027, gives drug developers a defined route for registering eligible studies while leaving them responsible for the scientific acceptability of the work. For companies commissioning Chinese studies and the contract research organizations running them, the practical issue is how to carry a consistent record from trial planning to the eventual marketing application.

The Center for Drug Evaluation (CDE) published the procedure and its accompanying questions and answers on November 6\. The notice is dated October 27; its appearance in a November 13 industry feed does not mark a new regulatory decision. The [notice reproduced by China Food and Drug Network](https://wap.cnpharm.com/c/2026-11-09/1110128.shtml?ref=chinapharmadesk.com) provides both final attachments.

Bioequivalence, or BE, studies assess whether a test medicine and a reference product perform comparably in the body. They are central to many generic-drug applications. The revised procedure also covers eligible studies supporting changes to already approved chemical drugs, including innovative medicines, and China's quality and efficacy consistency evaluation for marketed generics.

The operational implication is that BE oversight extends beyond a generic's initial filing. A manufacturer changing an approved product may also need to connect its batch, manufacturing process, reference medicine and clinical evidence through this system.

## A filing number starts a process

Under the [final procedure](https://wap.cnpharm.com/upload/resources/file/2026/11/09/196503.pdf?ref=chinapharmadesk.com), applicants must obtain ethics approval and sign a BE study contract before submitting the filing. Submission must occur at least 15 working days before study initiation. Successful submission generates a filing number; CDE can notify the applicant and revoke the filing within 15 working days where there are obvious dossier deficiencies or substantial safety risks.

The practical consequence for a sponsor-CRO schedule is that contracting, ethics review and dossier preparation must be aligned before the intended start. An immediately generated number cannot by itself settle whether the planned work will support a marketing application. The accompanying Q&A explicitly leaves that judgment to the technical review after registration submission.

Public trial registration must be completed before the first participant signs informed consent. If no participant signs within three years, the filing number expires automatically. A project that remains on hold therefore needs a separate decision about restarting its regulatory pathway; a filing is not an indefinite reservation for a future study.

## The endpoint and study population determine the route

The procedure separates studies eligible for BE filing from those requiring a clinical trial application. Studies using clinical endpoints to evaluate BE, and those for which the applicant considers a potential safety risk to require technical evaluation, fall into the latter route.

The [Q&A makes a further distinction for pharmacodynamic endpoints](https://wap.cnpharm.com/upload/resources/file/2026/11/09/196504.pdf?ref=chinapharmadesk.com): a study in healthy participants may use the filing route following a safety assessment, whereas one in patients requires a clinical trial application. Specially controlled medicines have additional conditions; the procedure does not remove their other regulatory requirements.

For a development team, choosing the route is therefore a study-design decision. Treating every comparison of a test product and a reference product as an administrative BE filing could put the project on the wrong path before recruitment begins.

The Q&A also distinguishes geography from the destination of the application. It says the procedure applies to BE studies conducted within China for registration purposes, including pilot and pivotal studies. Overseas BE data supporting a Chinese application must satisfy the relevant requirements for accepting foreign clinical trial data. This is consequential for a multinational sponsor deciding where to generate evidence: a plan to seek Chinese approval does not automatically place every overseas study in the domestic filing system.

## The development history follows the product

The required dossier includes details of the BE batch's manufacturer, production address, specific production line, batch number, formulation, process and API source, alongside the reference product and study organizations. These are the links that let a reviewer connect a clinical comparison to the product eventually submitted for approval.

Changes during development require an assessment. Where changes to the reference medicine, API source, formulation or process could alter behavior in the body and require a new BE study, the procedure calls for a new filing or clinical trial application. By contrast, the Q&A permits a protocol-only change to be explained and updated under the existing filing after a safety assessment.

There is a corresponding obligation at submission. Where development has involved several formulations or processes, the Q&A calls for previous filing numbers and study-completion information in CTD Module 2.7.1, the relevant section of the standardized registration dossier. For studies related to the formulation and process being submitted, the pivotal BE study requires the full package; other studies, including failed BE studies and pilot studies, may be submitted as report summaries, with full reports available if requested.

That distinction matters when a program moves between development partners or replaces a formulation. The record needed for registration includes more than the final successful comparison. Sponsors need access to the earlier filing and study history as well as the pivotal report; outsourcing the work does not transfer the applicant's responsibility for that record.

CDE also announced an upgraded filing platform on November 6, according to its [notice reproduced by the China Medical Information Query Platform](https://www.dayi.org.cn/information/626.html?ref=chinapharmadesk.com). Platform availability and the February effective date are separate facts. The notices do not establish shorter study timelines, lower costs or faster approvals.

For a sponsor preparing its next Chinese BE program, the useful preparation is to resolve the study route, align the contract and ethics timetable, and preserve the connection between each tested batch and the eventual application. Whether the revised process reduces avoidable rework will depend on how those responsibilities are handled in actual filings.

*Related on China Pharma Desk:* [*Charles River’s $470m Frontage CRO deal and China split*](https://chinapharmadesk.com/charles-river-frontage-470m-split/) *·* [*China Pharma Glossary: BE filing vs. CTA & GQCE*](https://chinapharmadesk.com/china-pharma-glossary/)